Unveiling the Latest Research on Resistant Hypertension

Published: Jan 17, 2024

Scientific research is paving the way for new treatments in resistant hypertension. Discover the latest advancements and what they mean for future care.
Contents

Aldosterone Synthase Inhibitors: A New Hope

Aldosterone synthase inhibitors, like lorundrostat and baxdrostat, are new medications showing promise in lowering blood pressure in resistant hypertension. These drugs work by affecting hormone levels that regulate blood pressure. Initial studies have shown positive results, although more research is needed.

The Role of Interfering RNA

Interfering RNA, such as zilebesiran, is being studied for its potential to reduce blood pressure by blocking certain proteins. This innovative approach could offer a novel way to manage resistant hypertension. Early trials have shown significant blood pressure reductions, highlighting the potential of RNA-based therapies.
Resistant hypertension is a condition where blood pressure remains high despite treatment with multiple antihypertensive medications. Recent research explores new therapies such as aldosterone synthase inhibitors and interfering RNA.

Exploring Combination Therapies

Research is also looking into combining existing medications for better results. Studies suggest that tailored combination therapies can enhance blood pressure control. This approach aims to maximize the benefits of current drugs while minimizing side effects.

Frequently Asked Questions

They're new drugs targeting hormones to lower blood pressure.

It blocks proteins that contribute to high blood pressure.

Yes, they can enhance blood pressure control with fewer side effects.

They offer a novel approach to managing resistant hypertension.

Future Directions

Ongoing research offers hope for more effective treatments for resistant hypertension.
Stay informed about cutting-edge research with Doctronic’s updates on resistant hypertension!

Related Articles

References

  1. Freeman MW, Halvorsen YD, Marshall W, et al. Phase 2 Trial of Baxdrostat for Treatment-Resistant Hypertension. N Engl J Med 2023; 388:395.
  2. Desai AS, Webb DJ, Taubel J, et al. Zilebesiran, an RNA Interference Therapeutic Agent for Hypertension. N Engl J Med 2023; 389:228.

This article has been reviewed for accuracy by one of the licensed medical doctors working for Doctronic. Always discuss health information with your healthcare provider.

AI Doctor Visit Required

Appointments available 24/7

πŸ˜€ πŸ˜€ πŸ˜€
stethoscope

Top licensed doctors

Available in all 50 states

dossier

Full service care

Prescriptions, referrals & treatment

check

No insurance needed

All notes available in Doctronic

15-min consultation. No hidden costs.

AI Doctor Visit Required
Close icon

Please Chat With Our AI Doctor First

Our AI doctor assessment helps our human doctors prepare for your video visit and provide better care

Lifebuoy

For safety reasons we have been forced to end this consultation.

If you believe this is a medical emergency please call 911 or your local emergency services immediately.

If you are experiencing emotional distress, please call the the Suicide & Crisis Lifeline at 988 or your local crisis services immediately.

Contact us

You can also email us at help@doctronic.ai

We aim to reply within 5-7 days

How likely are you to recommend Doctronic to friends or family?
Not likely at all Extremely likely